Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our tax obligations, the funds held in the trust account will not be released from the trust account until the earliest of: (i) the completion of our initial business combination, (ii) the redemption of any public shares properly tendered in connection with a stockholder vote to amend our amended and restated certificate of incorporation (a) to modify the substance or timing of our obligation to allow redemptions in connection with our initial business combination or to redeem or to redeem 100% of our public shares if we do not complete our initial business combination by March 30, 2023 or (b) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity, and (iii) the redemption of our public shares if we do not complete our initial business combination by March 30, 2023, subject to applicable law.
Our units began trading on September 28, 2021 on the NYSE under the symbol “BACA.U.” Commencing on November 18, 2021, the Class A common stock and warrants comprising the units began separate trading on the NYSE under the symbols “BACA” and “BACA WS,” respectively. On March 1, 2023, we received approval to transfer the listing of our Class A common stock from the NYSE to the NYSE American and on March 13, 2023, our Class A common stock began trading on the NYSE American under the symbol “BACA.” Following notice of delisting and suspension of trading of our warrants by the NYSE, effective February 3, 2023, our warrants are trading on the OTC Market under the symbol “BACA WS.” In addition, in connection with the transfer, effective March 13, 2023, any remaining units were mandatorily separated into its component parts and the units are no longer traded on the NYSE.
On March 1, 2023, we filed the Preliminary Schedule 14A relating to a special meeting of stockholders that is anticipated to be held on March 28, 2023 to approve the Charter Amendment Proposal which would, if implemented, allow us to extend the date by which we have to consummate an initial business combination from March 30, 2023 to September 30, 2023 or such earlier date as determined by our board of directors. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering and the private placement, our capital stock, debt or a combination of cash, stock and debt. We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete our initial business combination will be successful.
On March 21, 2023, we filed with the SEC a Current Report on Form 8-K relating to the entry into a non-redemption agreement (the “Non-Redemption Agreement”) with the sponsor, one or more unaffiliated third party or parties in exchange for such third party or third parties agreeing not to redeem an aggregate of 1,959,269 shares of our Class A common stock, sold in our initial public offering (the “Non-Redeemed Shares”) at the special meeting of stockholders discussed above. In exchange for the foregoing commitments not to redeem such shares, our sponsor has agreed to transfer to such third party or third parties an aggregate of 489,819 shares of our Class A common stock held by the sponsor immediately following consummation of an initial business combination if they continue to hold such Non-Redeemed Shares through the special meeting. The Non-Redemption Agreement is not expected to increase the likelihood that the Charter Amendment Proposal is approved by our stockholders but will increase the amount of funds that remain in our trust account following the special meeting.
Results of Operations
We have neither engaged in any operations nor generated any revenues to date. Our only activities from June 1, 2021 (inception) through December 31, 2022 were organizational activities and those necessary to prepare for our initial public offering, and since our initial public offering, our activity has been limited to identifying a target company for a business combination. We do not expect to generate any operating revenues until after the completion of our initial business combination. We generate non-operating income in the form of interest income on marketable securities held in the trust account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, a business combination.
For the year ended December 31, 2022, we had net income of $10,923,646, which consists of operating costs of $(1,622,628), income tax expense of $749,165 offset by interest income of $3,867,960 and change in fair value of derivative warrant liabilities of $9,427,479.
For the period from June 1, 2021 (inception) through December 31, 2021, we had net income of $8,323,175, which consists of operating costs of $(392,746), offset by interest earned on marketable securities held in the trust account of $5,128 and offering costs associated with derivative warrant liabilities of $(1,780,157) and change in fair value of derivative warrant liabilities of $10,490,950.
Liquidity and Capital Resources
As of December 31, 2022 and 2021, we had cash of $250,453 and $670,762, respectively. Until the consummation of our initial public offering, our only source of liquidity was an initial purchase of founder shares by our sponsor and loans from our sponsor.
On September 30, 2021, we consummated our initial public offering of 25,000,000 units, at $10.00 per unit, generating gross proceeds of $250,000,000. Simultaneously with the closing of our initial public offering, we consummated the private placement of 7,000,000 private placement warrants to our sponsor at a price of $1.00 per private placement warrant, generating gross proceeds of $7,000,000.
Following our initial public offering (including the partial exercise of the over-allotment option), and the sale of the private placement warrants, a total of $275,100,000 was placed in the trust account. We incurred $15,636,971 in transaction costs, including $5,502,000 of underwriting commissions, $9,628,500 of deferred underwriting commissions and $506,471 of other costs.
For the year ended from December 31, 2022, cash used in operating activities was $608,729. Net income of $10,923,646 was affected by interest earned on marketable securities held in the trust account of $(3,865,691), change in fair value of derivative warrant liabilities of $(9,427,479) and changes in operating and liabilities, which provided $1,760,795 of cash from operating activities.
For the period from June 1, 2021 (inception) through December 31, 2021, cash used in operating activities was $847,766. Net income of $8,323,175 was affected by interest earned on marketable securities held in the trust account of $(5,128), offering costs associated with derivative warrant liabilities of $1,780,157 and change in fair value of derivative warrant liabilities of $(10,490,950) and changes in operating assets and liabilities, which used $(455,020) of cash from operating activities.
44